Hormone response in ovarian cancer: Time to reconsider as a clinical target?

Francesmary Modugno, Robin Laskey, Ashlee L. Smith, Courtney L. Andersen, Paul Haluska, Steffi Oesterreich

Research output: Contribution to journalReview article

66 Scopus citations

Abstract

Ovarian cancer is the sixth most common cancer worldwide among women in developed countries and the most lethal of all gynecologic malignancies. There is a critical need for the introduction of targeted therapies to improve outcome. Epidemiological evidence suggests a critical role for steroid hormones in ovarian tumorigenesis. There is also increasing evidence from in vitro studies that estrogen, progestin, and androgen regulate proliferation and invasion of epithelial ovarian cancer cells. Limited clinical trials have shown modest response rates; however, they have consistently identified a small subset of patients that respond very well to endocrine therapy with few side effects. We propose that it is timely to perform additional well-designed trials that should include biomarkers of response.

Original languageEnglish (US)
Pages (from-to)R255-R279
JournalEndocrine-Related Cancer
Volume19
Issue number6
DOIs
StatePublished - Dec 1 2012

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Oncology
  • Endocrinology
  • Cancer Research

Fingerprint Dive into the research topics of 'Hormone response in ovarian cancer: Time to reconsider as a clinical target?'. Together they form a unique fingerprint.

  • Cite this

    Modugno, F., Laskey, R., Smith, A. L., Andersen, C. L., Haluska, P., & Oesterreich, S. (2012). Hormone response in ovarian cancer: Time to reconsider as a clinical target? Endocrine-Related Cancer, 19(6), R255-R279. https://doi.org/10.1530/ERC-12-0175